📊 ENOV Key Takeaways
Is Enovis CORP (ENOV) a Good Investment?
Enovis is experiencing severe operational distress with a -50% operating margin and -52.7% net margin, converting a healthy 59.8% gross margin into substantial net losses. While revenue growth of 6.7% YoY and positive operating cash flow of $217.3M suggest underlying business activity, the company is burning through equity rapidly with ROE of -79.5%, indicating fundamental profitability challenges that must be resolved before investment consideration.
Enovis shows respectable top-line growth and strong gross margins, but the fundamental picture is dominated by extreme operating and net losses, deeply negative returns on capital, and weak free cash flow conversion. Liquidity is adequate near term, but low cash balances, high leverage, and negative interest coverage materially weaken financial flexibility and make the current growth profile lower quality.
Why Buy Enovis CORP Stock? ENOV Key Strengths
- Solid gross margin of 59.8% demonstrates strong pricing power and cost-of-goods-sold efficiency in core operations
- Positive operating cash flow of $217.3M indicates the company can still generate cash from business operations despite net losses
- Revenue growth of 6.7% YoY shows market demand and ability to expand top line in orthopedic appliances sector
- Adequate liquidity with 2.02x current ratio and minimal cash burn provides operational runway
- Revenue grew 6.7% year over year, indicating continued demand growth
- Gross margin of 59.8% suggests a solid underlying product mix and pricing structure
- Current ratio of 2.02x and quick ratio of 1.04x indicate acceptable short-term liquidity
ENOV Stock Risks: Enovis CORP Investment Risks
- Massive operating losses of -$1.1B and net losses of -$1.2B indicate severe structural profitability problems requiring immediate operational restructuring
- Negative ROE of -79.5% and ROA of -30.9% demonstrate extremely poor capital efficiency and value destruction for shareholders
- Operating margin of -50% is unsustainable; company is losing $0.50 on every dollar of revenue generated, suggesting unfixable cost structure or massive one-time charges
- Free cash flow of only $19.9M (0.9% FCF margin) after capex represents dangerous margin for error; minimal buffer for debt service
- Long-term debt of $1.3B with negative interest coverage ratio of -32.3x creates refinancing risk and financial instability
- Deteriorating EPS of -$20.75 per share with -39% YoY decline indicates shareholder value destruction is accelerating
- Operating margin of -50.0% and net margin of -52.7% indicate severe profitability pressure
- Free cash flow was only $19.92M on $2.25B of revenue, showing weak cash conversion after capital spending
- Cash of $36.39M versus $1.30B of long-term debt and negative interest coverage creates balance sheet risk
Key Metrics to Watch
- Operating margin recovery timeline - critical to confirm losses are temporary or structural
- Operating cash flow sustainability - whether $217.3M can be maintained as net losses continue
- Debt refinancing plans and covenant compliance given negative interest coverage
- Gross margin stability - whether 59.8% level can be maintained amid operational restructuring
- Management commentary on path to profitability and estimated turnaround timeline
- Operating margin and net income trend
- Free cash flow generation relative to debt and interest burden
Enovis CORP (ENOV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 0.9% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.02x current ratio provides a solid financial cushion.
ENOV Profit Margin, ROE & Profitability Analysis
ENOV vs Healthcare Sector: How Enovis CORP Compares
How Enovis CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enovis CORP Stock Overvalued? ENOV Valuation Analysis 2026
Based on fundamental analysis, Enovis CORP shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enovis CORP Balance Sheet: ENOV Debt, Cash & Liquidity
ENOV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enovis CORP's revenue has declined by 42% over the 5-year period, indicating business contraction. The most recent EPS of $-0.61 indicates the company is currently unprofitable.
ENOV Revenue Growth, EPS Growth & YoY Performance
ENOV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $505.2M | -$31.5M | $-0.58 |
| Q2 2025 | $525.2M | -$18.6M | $-0.34 |
| Q1 2025 | $516.3M | -$56.0M | $-0.98 |
| Q3 2024 | $417.5M | -$2.9M | $-0.05 |
| Q2 2024 | $428.5M | -$10.0M | $-0.18 |
| Q1 2024 | $406.2M | -$23.4M | $-0.43 |
| Q3 2023 | $383.8M | -$2.9M | $-0.05 |
| Q2 2023 | $395.1M | -$10.0M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Enovis CORP Dividends, Buybacks & Capital Allocation
ENOV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enovis CORP (CIK: 0001420800)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENOV
What is the AI rating for ENOV?
Enovis CORP (ENOV) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENOV's key strengths?
Claude: Solid gross margin of 59.8% demonstrates strong pricing power and cost-of-goods-sold efficiency in core operations. Positive operating cash flow of $217.3M indicates the company can still generate cash from business operations despite net losses. ChatGPT: Revenue grew 6.7% year over year, indicating continued demand growth. Gross margin of 59.8% suggests a solid underlying product mix and pricing structure.
What are the risks of investing in ENOV?
Claude: Massive operating losses of -$1.1B and net losses of -$1.2B indicate severe structural profitability problems requiring immediate operational restructuring. Negative ROE of -79.5% and ROA of -30.9% demonstrate extremely poor capital efficiency and value destruction for shareholders. ChatGPT: Operating margin of -50.0% and net margin of -52.7% indicate severe profitability pressure. Free cash flow was only $19.92M on $2.25B of revenue, showing weak cash conversion after capital spending.
What is ENOV's revenue and growth?
Enovis CORP reported revenue of $2.2B.
Does ENOV pay dividends?
Enovis CORP pays dividends, with $5.1M distributed to shareholders in the trailing twelve months.
Where can I find ENOV SEC filings?
Official SEC filings for Enovis CORP (CIK: 0001420800) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENOV's EPS?
Enovis CORP has a diluted EPS of $-20.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENOV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Enovis CORP has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENOV stock overvalued or undervalued?
Valuation metrics for ENOV: ROE of -79.5% (sector avg: 15%), net margin of -52.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENOV stock in 2026?
Our dual AI analysis gives Enovis CORP a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENOV's free cash flow?
Enovis CORP's operating cash flow is $217.3M, with capital expenditures of $197.4M. FCF margin is 0.9%.
How does ENOV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -52.7% (avg: 12%), ROE -79.5% (avg: 15%), current ratio 2.02 (avg: 2).